Priothera Ltd. today announces that the U.S. Food and Drug Administration (FDA) has provided clearance to proceed with the Company's Investigational New | New Investigational Drug for Acute Myeloid Leukemia Patients
/PRNewswire/ Priothera Ltd, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator mocravimod, today announces.
€1.5 million loan will further support clinical manufacture of mocravimod for the adjunctive treatment of Acute Myeloid Leukemia (AML) DUBLIN and SAINT-LOUIS, France, April 4, 2022
- Mocravimod is being developed as a potential best-in-class adjunctive and maintenance therapy to enhance the curative potential of HSCT for AML patients - A global registration-enabling